Although patients may regain nearly two-thirds of their lost weight on GLP-1 RAs after cessation of the drug16, this early positive reinforcement may serve as an incentive to pursue a long-term, multipronged approach to combat obesity. The gene discussed is GLP1R; the disease is obesity disorder.